Identifying novel treatment options for ovarian carcinosarcoma

Identifying novel treatment options for ovarian carcinosarcoma

Project details

Ovarian carcinosarcoma (OCS) and high grade serous endometrial cancer (HGSEC) are rare and very aggressive gynaecological cancers. Due to their rarity, there are few evidence-based treatment options for these cancers because supportive data is simply not available. Standard treatment comprises surgery with platinum/taxane-based chemotherapy. Both OCS and HGSEC have poor responses to chemotherapy compared to other more common gynaecological cancer subtypes.

This project will involve the analysis of patient samples using a variety of techniques including genomics, 3D organoid culture, live cell imaging, immune profiling, drug library screening, and CRISPR screening. The aim is to identify pathways that mediate response to conventional chemotherapeutics and that show potential for targeting with novel agents, to inform clinical trial design in these under-studied cancers.

About our research group

The Scott Laboratory has a strong emphasis on research that has potential for clinical translation. Our relatively large laboratory of 15 is made up of a combination of clinician scientists, post-doctoral fellows, students and research assistants. We have a strong collaborative ethic and while the lab is working on two main projects, rare cancer and ovarian cancer, technical expertise and resources are shared between both groups. There is a variety of expertise within the group including bioinformatics, genomics and cell biology.

 

Email supervisors

 

Researchers:

Professor Clare Scott

Professor Clare Scott
Professor
Clare
Scott
Joint Division Head
Dr Holly Barker in the lab
Dr
Holly
Barker
ACRF Cancer Biology and Stem Cells division
Dr Kristy Shield-Artin
Dr
Kristy
Shield-Artin
ACRF Cancer Biology and Stem Cells

Project Type: